RenaSci is pleased to welcome Dr Nick Moore on board as Senior Director, Business Development. Nick is an internationally recognised drug discovery and development specialist who has spent nearly forty years working in the field of in vivo pharmacology. Previous roles include research appointments at Eli Lilly, Lundbeck Research USA and Albany Molecular Research Inc (AMRI) and business development positions at Brains On-Line and Charles River Laboratories. He earned his PhD in Neuropharmacology from the University of Birmingham and career highlights include a key involvement in the development of Lilly’s anti-psychotic drug Zyprexa (olanzapine).
One of Nick’s key tasks will be to ensure that the synergistic in vitro and in vivo services and drug discovery expertise offered by RenaSci and our colleagues in Sygnature Discovery are maximised for the benefit of our clients.